Key Pharmacologic Principles and Drug-Drug Interactions in HIV Patient Care
Summary
- Caution is warranted when beta-blockers are coadministered with any PI; beta-blockers that are not metabolized by CYP 450 should be considered and dose adjustment based on clinical response may be necessary[DHHS ART]
- Beta-blockers also interact with cobicistat/elvitegravir/emtricitabine/tenofovir DF and cobicistat/elvitegravir/emtricitabine/tenofovir AF; clinical monitoring is recommended, and beta-blocker dose reductions may be required[FDA COBI/EVG/TDF/FTC; FDA COBI/EVG/TAF/FTC]
- Consider using beta-blockers that are not metabolized by CYP 450 enzymes[DHHS ART]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content